Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Sofiemyr – page 32

616 clinical trials in Sofiemyr, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Sofiemyr at a glance
616
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

616 trials in Sofiemyr

Open in trial search

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:SKB410
  • Sponsor:Merck Sharp & Dohme LLC

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:GSK4527226
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Renal transplant

Not recruiting

Comparing tacrolimus and mycophenolate mofetil bioequivalence in kidney transplant recipients taking immunosuppressive medications

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Oslo University Hospital HF

Diabetic neuropathy+1

Not recruiting

Study of cagrilintide and semaglutide combination versus placebo in people with type 2 diabetes and painful diabetic peripheral neuropathy

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study of laroprovstat (AZD0780) tablets to lower cholesterol levels in adults with inherited high cholesterol condition (heterozygous familial hypercholesterolemia)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.